Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type
Authors:
- 1 January 1992
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 42 (1) , 89-93
Abstract
Acetyl-L-carnitine (ALC), a physiological component of the L-carnitine family, has been proposed for treating Alzheimer's disease in pharmacological doses. As this condition requires prolonged therapy, its kinetics has been examined after a multiple dose regimen, involving different routes of administration, in 11 patients suffering from Senile Dementia of Alzheimer Type. The study design comprised a 3-day basal observation period, sham treatment with repeated blood sampling; treatment with 30 mg·kg−1 i.v. given twice for 10 days (plasma kinetics was studied on the 7th day), and 50 days of 2.0 g/day p.o. given in three daily doses. Total acid soluble L-carnitine, L-carnitine and acetyl-L-carnitine in plasma and CSF were evaluated using an enantioselective radioenzyme assay. Short chain L-carnitine esters were calculated as the difference between total and free-L-carnitine. The plasma concentrations of individual components of the L-carnitine family did not change during the three days of the basal period, nor were they affected during the sham therapy period. Following the i.v. bolus injections, the plasma concentrations showed a biphasic curve, with average t1/2 of 0.073 h and 1.73 h, respectively. At the end of oral treatment, plasma acetyl-L-carnitine and L-carnitine short chain esters were significantly higher than during the run-in phase. The CSF concentrations paralleled those in plasma, suggesting that ALC easily crosses the blood-brain barrier. It is concluded that i.v. and oral administration of multiple doses of ALC can increase its plasma and CSF concentration in patients suffering from Alzheimer's disease.Keywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetics of oral acetyl-L-carnitine in renal impairmentEuropean Journal of Clinical Pharmacology, 1990
- Chromatographic and non-chromatographic assay of L-carnitine family componentsJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Metabolism and disposition of intravenously administered acetyl-L-carnitine in healthy volunteersEuropean Journal of Clinical Pharmacology, 1989
- Multicenter clinical placebo‐controlled study with acetyl‐l‐carnitine (LAC) in the treatment of mildly demented elderly patientsDrug Development Research, 1988
- Acetyl-L-Carnitine in the Rat’s Hippocampus Aging: Morphological, Endocrine and Behavioral Correlates1988
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Pharmacokinetics1982
- The Action of Carnitines on Cortical NeuronsCanadian Journal of Physiology and Pharmacology, 1971
- NEUROMUSCULAR BLOCKING ACTIVITY AND OTHER PHARMACOLOGIC PROPERTIES OF VARIOUS CARNITINE DERIVATIVESThe Journal of Pharmacology and Experimental Therapeutics, 1967
- Carnitine and Its Role in Fatty Acid Metabolism* *Work reviewed from this laboratory was supported by grants A-1465 and A-1682 from the National Institutes of Health.1963